Opendata, web and dolomites

OPTOGENERAPY SIGNED

Optogenetic Protein Therapy for Multiple Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPTOGENERAPY project word cloud

Explore the words cloud of the OPTOGENERAPY project. It provides you a very rough idea of what is the project "OPTOGENERAPY" about.

biomaterials    neos    encapsulate    device    release    confinement    competences    implanted    porous    rejection    optimal    moulding    electronic    least    standard    class    autonomy    industrial    penetration    implant    bio    market    wireless    overcoming    performance    miniaturization    manufacturing    validate    meets    losses    efficiency    leader    adherence    2014    minimal    implantation    micro    light    safety    responds    engineered    engineering    prevent    genetically    listed    adverse    time    biocompatibility    embedding    science    implants    offers    invasiveness    boston    innovation    szlig    immune    proposes    validated    clear    ultrasion    active    membrane    intravenous    prototype    easily    synthetic    huge    magazine    ifn    combining    demands    peaks    optogenetic    revolutionize    drug    proof    interferon    optical    scientist    powered    genexplain    preclinically    polymeric    replacing    subcutaneously    gene    cells    intensive    prevents    competitiveness    barrier    smes    enhanced    cell    stability    worldwide    cellular    neuromodulation    chamber    30    saving    optoelectronics    multiple    treatment    optogenetics    therapies    acts    computer    optogenerapy    technological    push    removed    months    sclerosis    plans    sealed    discontinuation    pull    big    subcutaneous    scientific   

Project "OPTOGENERAPY" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO EURECAT 

Organization address
address: AVENIDA UNIVERSITAT AUTONOMA 23
city: CERDANYOLA DEL VALLES (BARCELONA)
postcode: 8290
website: www.eurecat.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.optogenerapy.eu
 Total cost 6˙233˙257 €
 EC max contribution 4˙777˙257 € (77%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO EURECAT ES (CERDANYOLA DEL VALLES (BARCELONA)) coordinator 1˙256˙557.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 951˙345.00
3    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 805˙880.00
4    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 386˙100.00
5    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) participant 322˙590.00
6    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 303˙375.00
7    POLITECHNIKA LODZKA PL (LODZ) participant 255˙000.00
8    TWOPTICS SYSTEMS DESIGN SL ES (BARCELONA) participant 246˙410.00
9    ULTRASION S.L. ES (CERDANYOLA DEL VALLES) participant 172˙500.00
10    ASOCIACION ESPANOLA DE NORMALIZACION ES (MADRID) participant 77˙500.00
11    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 0.00

Map

 Project objective

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.

The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß.

Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs.

It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness.

The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science.

In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands.

BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTOGENERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTOGENERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.)

SYNAMERA (2015)

Synergies in Nanotechnologies, Materials and Production in the European Research Area

Read More  

SMARTFAN (2018)

Smart by Design and Intelligent by Architecture for turbine blade fan and structural components systems

Read More  

CORNET (2018)

Multiscale modelling and characterization to optimize the manufacturing processes of Organic Electronics materials and devices

Read More